A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

S. Tam, Constantine; Opat, Stephen; D’Sa, Shirley; Jurczak, Wojciech; Lee, Hui‐Peng; Cull, Gavin; G. Owen, Roger; Marlton, Paula; E. Wahlin, Björn; García‐Sánz, Ramón; O. McCarthy, Helen; P. Mulligan, Stephen; Tedeschi, Alessandra; J. Castillo, Jorge; Czyz, Jaroslaw; Fernández de Larrea, Carlos; Belada, David; N. Libby, Edward; Matous, Jeffrey; Motta, Marina; Siddiqi, Tanya; Tani, Monica; Trněný, Marek; C. Minnema, Monique; Buske, Christian; Leblond, Véronique; Trotman, Judith; Chan, Wai‐Yee; Schneider, Jingjing; Ro, Sunhee; Cohen, Aileen; Huang, Jane; Α. Dimopoulos, Meletios

doi:10.1182/blood.2020006844

Public

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Published in Blood • Jul 31, 2020

Authors:

Constantine S. Tam

Stephen Opat

Shirley D’Sa

Abstract

Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in pati...

Subject

Ibrutinib

Waldenstrom macroglobulinemia

Macroglobulinemia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!